A Phase 3 interventional study of adalimumab and Placebo in Rheumatoid Arthritis, sponsored by Abbott. Completed at 86 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 23rd largest by enrollment, is one of 7 that started in 2007, is one of 36 in phase 3, and was the 22nd registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 420 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2007, is one of 14 in phase 3, and was the 17th registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo and demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab every other week.
The objective of this study is to demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo as measured by ACR20 response criteria following 12 weeks of therapy. The study is also designed to demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab eow as measured by ACR20 response criteria at Week 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
Drug: Placebo
40 mg every other week
Drug: adalimumab
80 mg monthly
Drug: adalimumab
Pre-filled syringe. See arm for more detail
Also known as: ABT-D2E7, Humira
Pre-filled syringe. See arm for more detail
Pre-filled syringe. See arm for more detail
Also known as: ABT-D2E7, Humira
The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)
Comparison of adalimumab 80 mg monthly dose versus placebo and adalimumab 40 mg eow in the number of responders with ACR criteria improvement consisting of 20%, (ACR20) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20% improvement in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and \[5\] C-reactive protein (CRP) at each visit
Time frame: Week 12
Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
Time frame: Baseline and Week 12
Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
Time frame: Baseline and Week 12
Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
Time frame: Baseline and Week 12
Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
Time frame: Baseline and Week 12
The study was conducted at 72 sites in the United States, Canada, Puerto Rico, Germany, the United Kingdom, and Australia. Subjects received over the course of 24 weeks either 80 mg adalimumab monthly, 40 mg adalimumab every other week (eow), or placebo (12 weeks) followed by 40 mg adalimumab eow (12 weeks).
| Milestone | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly |
|---|---|---|---|
| Started | 56 | 159 | 205 |
| Completed | 48 | 146 | 182 |
| Not completed | 8 | 13 | 23 |
| Withdrew: Adverse event | 2 | 7 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 7 |
| Withdrew: Other | 4 | 4 | 8 |
| Milestone | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly |
|---|---|---|---|
| Started | 48 | 146 | 182 |
| Completed | 45 | 137 | 175 |
| Not completed | 3 | 9 | 7 |
| Withdrew: Adverse event | 1 | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
| Withdrew: Other | 2 | 6 | 0 |
Comparison of adalimumab 80 mg monthly dose versus placebo and adalimumab 40 mg eow in the number of responders with ACR criteria improvement consisting of 20%, (ACR20) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20% improvement in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and \[5\] C-reactive protein (CRP) at each visit
| participants | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly |
|---|---|---|---|
| Responders | 19 | 80 | 97 |
| Nonresponders | 37 | 79 | 108 |
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
| units on a score | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly |
|---|---|---|---|
| Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed) | -0.11 ± 0.488 | -0.41 ± 0.508 | -0.39 ± 0.536 |
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
| units on a score | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly |
|---|---|---|---|
| Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF]) | -0.12 ± 0.484 | -0.40 ± 0.507 | -0.37 ± 0.537 |
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
| units on a score | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly |
|---|---|---|---|
| Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed) | 0 ± 0 | -0.26 ± 0.081 | -0.24 ± 0.079 |
The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.
| units on a score | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly |
|---|---|---|---|
| Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF]) | 0 ± 0 | -0.24 ± 0.077 | -0.21 ± 0.075 |
Collected over 24 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Every Other Week (Eow)-Period 1 | — | 5/57 (8.8%) | 13/57 (22.8%) |
| Adalimumab 40 mg Eow -Period 1 | — | 8/164 (4.9%) | 29/164 (17.7%) |
| Adalimumab 80 mg Monthly-Period 1 | — | 4/211 (1.9%) | 38/211 (18%) |
| Placebo/Adalimumab 40 mg Eow-Period 2 | — | 1/49 (2%) | 6/49 (12.2%) |
| Adalimumab 40 mg Eow-Period 2 | — | 5/151 (3.3%) | 14/151 (9.3%) |
| Adalimumab 80 mg Monthly - Period 2 | — | 12/188 (6.4%) | 11/188 (5.9%) |
| Event | Placebo Every Other Week (Eow)-Period 1 | Adalimumab 40 mg Eow -Period 1 | Adalimumab 80 mg Monthly-Period 1 | Placebo/Adalimumab 40 mg Eow-Period 2 | Adalimumab 40 mg Eow-Period 2 | Adalimumab 80 mg Monthly - Period 2 |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/57 | 4/164 | 0/211 | 0/49 | 1/151 | 0/188 |
| DeathGeneral disorders | 0/57 | 0/164 | 0/211 | 1/49 | 0/151 | 0/188 |
| Drug toxicityInjury, poisoning and procedural complications | 1/57 | 0/164 | 0/211 | 0/49 | 0/151 | 0/188 |
| Femur fractureInjury, poisoning and procedural complications | 1/57 | 0/164 | 0/211 | 0/49 | 0/151 | 0/188 |
| Patella fractureInjury, poisoning and procedural complications | 1/57 | 0/164 | 0/211 | 0/49 | 0/151 | 0/188 |
| ArteriosclerosisVascular disorders | 1/57 | 0/164 | 0/211 | 0/49 | 0/151 | 0/188 |
| HaematomaVascular disorders | 1/57 | 0/164 | 0/211 | 0/49 | 0/151 | 0/188 |
| Urinary tract infectionInfections and infestations | 0/57 | 2/164 | 0/211 | 0/49 | 0/151 | 1/188 |
| CellulitisInfections and infestations | 0/57 | 0/164 | 2/211 | 0/49 | 1/151 | 0/188 |
| Ankle fractureInjury, poisoning and procedural complications | 0/57 | 0/164 | 0/211 | 0/49 | 1/151 | 0/188 |
| Event | Placebo Every Other Week (Eow)-Period 1 | Adalimumab 40 mg Eow -Period 1 | Adalimumab 80 mg Monthly-Period 1 | Placebo/Adalimumab 40 mg Eow-Period 2 | Adalimumab 40 mg Eow-Period 2 | Adalimumab 80 mg Monthly - Period 2 |
|---|---|---|---|---|---|---|
| diarrhoeaGastrointestinal disorders | 4/57 | 2/164 | 4/211 | 0/49 | 0/151 | 0/188 |
| upper respiratory tract infectionInfections and infestations | 4/57 | 5/164 | 11/211 | 3/49 | 4/151 | 6/188 |
| nasopharyngitisInfections and infestations | 3/57 | 8/164 | 2/211 | 3/49 | 10/151 | 5/188 |
| nauseaGastrointestinal disorders | 3/57 | 9/164 | 13/211 | 0/49 | 0/151 | 0/188 |
| dizzinessNervous system disorders | 3/57 | 4/164 | 5/211 | 0/49 | 0/151 | 0/188 |
| headacheNervous system disorders | 3/57 | 8/164 | 10/211 | 0/49 | 0/151 | 0/188 |
| coughRespiratory, thoracic and mediastinal disorders | 3/57 | 1/164 | 1/211 | 0/49 | 0/151 | 0/188 |
| Age, Customized(participants) | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly | Total |
|---|---|---|---|---|
| < 65 years | 43 | 113 | 148 | 304 |
| >= 65 years | 13 | 46 | 57 | 116 |
| Age Continuous(years) | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly | Total |
|---|---|---|---|---|
| Mean | 54.4 ± 12.46 | 57.2 ± 12.79 | 56.3 ± 12.43 | 56.4 ± 12.58 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab 40 mg Eow | Adalimumab 80 mg Monthly | Total |
|---|---|---|---|---|
| Female | 43 | 122 | 149 | 314 |
| Male | 13 | 37 | 56 | 106 |
The record gives a start of Dec 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab